Cargando…

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

We investigated the serum concentration of total metalloproteinase-9 (tMPP-9), active MMP-9 (aMMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in a group of 41 patients with SLE and 20 healthy controls. Serum levels of tMMP-9 and TIMP-1 were assessed by an enzyme-linked immunosorbent ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robak, Ewa, Wierzbowska, Agnieszka, Chmiela, Magdalena, Kulczycka, Liliana, Sysa-Jędrejowska, Anna, Robak, Tadeusz
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2006
Materias:	Research Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1570389/ https://www.ncbi.nlm.nih.gov/pubmed/16864898 http://dx.doi.org/10.1155/MI/2006/17898

Ejemplares similares

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (2004)

Quality of life and satisfaction with life in SLE patients—the importance of clinical manifestations
por: Kulczycka, Lilianna, et al.
Publicado: (2010)

Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (1999)

Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients.
por: Wozniacka, Anna, et al.
Publicado: (2003)

Exhaled IL-8 in Systemic Lupus Erythematosus with and without Pulmonary Fibrosis
por: Nielepkowicz-Goździńska, Agnieszka, et al.
Publicado: (2014)

Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Klonowska-Szymczyk, Agnieszka, et al.
Publicado: (2014)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes
por: Robak, E., et al.
Publicado: (1996)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
por: Robak, E, et al.
Publicado: (2001)

The Imbalance Between Metalloproteinases and Their Tissue Inhibitors Is Involved in the Pathogenesis of Dermatitis Herpetiformis
por: Zebrowska, Agnieszka, et al.
Publicado: (2005)

Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma
por: Matulka, Marlena, et al.
Publicado: (2019)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease duration
por: Hawro, Tomasz, et al.
Publicado: (2010)

Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients
por: Wojciechowska, Milena, et al.
Publicado: (2013)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Vitamin D Receptor Gene BsmI Polymorphism in Polish Patients with Systemic Lupus Erythematosus
por: Kaleta, Beata, et al.
Publicado: (2013)

Assessment of serum concentrations of matrix metalloproteinase 1, matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases 1 in atopic dermatitis in correlation with disease severity and epidermal barrier parameters
por: Basałygo, Magdalena, et al.
Publicado: (2021)

Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Endometriosis Menstrual Blood
por: Madjid, Tita Husnitawati, et al.
Publicado: (2020)

Important role of matrix metalloproteinase 9 in epileptogenesis
por: Wilczynski, Grzegorz M., et al.
Publicado: (2008)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
por: Gora-Tybor, Joanna, et al.
Publicado: (2003)

The Expression of the SLIT–ROBO Family in Adult Patients with Acute Myeloid Leukemia
por: Gołos, Aleksandra, et al.
Publicado: (2019)

The regulation of trophoblast invasion and decidual reaction by matrix metalloproteinase‐2, metalloproteinase‐7, and metalloproteinase‐9 expressions in the rat endometrium
por: Hamutoğlu, Rasim, et al.
Publicado: (2020)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Expression of Matrix Metalloproteinase-2/9 and Tissue Inhibitor of Metalloproteinase-1/2 as Predictive Factors in Oropharyngeal Squamous Cell Carcinoma
por: Burduk, Pawel-Krzysztof, et al.
Publicado: (2019)

Relationship between Circulating Serpina3g, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 and -2 with Chronic Obstructive Pulmonary Disease Severity
por: Uysal, Pelin, et al.
Publicado: (2019)

The Significance of Matrix Metalloproteinase 9 (MMP-9) and Metalloproteinase 2 (MMP-2) in Urinary Bladder Cancer
por: Kudelski, Jacek, et al.
Publicado: (2023)

The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients
por: Mroczko, Barbara, et al.
Publicado: (2010)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018)

Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
por: Zhang, Yongxiang, et al.
Publicado: (2020)

Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis
por: Tveita, Anders, et al.
Publicado: (2008)

The role of endocan and selected pro-inflammatory cytokines in systemic lupus erythematosus
por: Tokarska, Kamila, et al.
Publicado: (2019)

Epigenetics of Epileptogenesis-Evoked Upregulation of Matrix Metalloproteinase-9 in Hippocampus
por: Zybura-Broda, Katarzyna, et al.
Publicado: (2016)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
por: Todd, Jamie L., et al.
Publicado: (2020)

Matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in sera and urine of patients with renal carcinoma
por: DI CARLO, ANGELINA
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8jrvbbavc6jhc045h6r85cn0eb